By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Basilea Pharmaceutica 

Grenzacherstrasse 487

Basel    CH-4005  Switzerland
Phone: 41-61-6061-111 Fax: 41-61-6061-112


Basilea Pharmaceutica is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through its fully integrated research and development operations the company focuses on the development of innovative antibiotics, antifungals and oncology drugs, targeting the medical challenge of resistance and non-response to current treatment options.


October 17, 2000


Founder: Jan G. J. van de Winkel, Ph.D.

CEO: Ronald Scott

CMO (Medical): Achim Kaufhold

CTO: G√ľnter Ditzinger

CFO: Donato Spota

CSO (Scientific): Laurenz Kellenberger


Please click here for.


Please click here for clinical trial information.


All Products

Key Statistics

Ownership: Public

Web Site: Basilea
Symbol: BSLN.SW

Company News
Basilea (BSLN.SW) Announces Agreement With FDA On Special Protocol Assessments For Antibiotic Ceftobiprole Phase III Clinical Studies In Bloodstream And Skin Infections 4/21/2017 8:26:56 AM
Basilea (BSLN.SW) Ends Further Development of Inhaled Antibiotic BAL30072 8/15/2016 10:46:19 AM
Clinigen Announces Partnership With Basilea (BSLN.SW) To Initiate A Managed Access Program For Isavuconazole To Treat Patients With Invasive Fungal Infections In Europe 6/9/2016 12:46:27 PM
Basilea (BSLN.SW) Shareholders Approve All Resolutions Proposed By The Board Of Directors At The Ordinary General Meeting Of Shareholders 4/21/2016 10:49:27 AM
Basilea (BSLN.SW) Wins $100 Million Contract to Fund Phase III Ceftobiprole Program 4/20/2016 6:49:47 AM
GlaxoSmithKline (GSK) Kills U.S. Part of Eczema Treatment Deal With Basilea (BSLN.SW) 1/22/2016 5:57:43 AM
Basilea Pharmaceutica (BSLN.SW) Reports Start Of First-In-Human Phase I Oncology Study With Oral Panraf Kinase Inhibitor 5/4/2015 2:47:29 PM
Basilea Pharmaceutica (BSLN.SW) Shareholders Approve All Resolutions Proposed By The Board Of Directors At The Ordinary General Meeting Of Shareholders 4/29/2015 10:52:52 AM
Basilea Pharmaceutica (BSLN.SW) Reports U.S. FDA Approval Of Isavuconazole For The Treatment Of Invasive Aspergillosis And Invasive Mucormycosis 3/9/2015 7:25:46 AM
Basilea Pharmaceutica (BSLN.SW) Announces Launch Of Antibiotic Zevtera(R) (Ceftobiprole Medocaril) In Germany 12/5/2014 9:37:37 AM